At Stanford University Medical Center, researchers made an unexpected discovery: the same medication that helps people shed dangerous weight in type 2 diabetes may also strengthen their bones. A large-scale study presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago, found that semaglutide was associated with a 15% reduction in bone fractures compared with other anti-obesity drugs—a finding that upends previous assumptions about rapid weight loss and skeletal health.
The result matters because it challenges a troubling paradox: while glucagon-like peptide-1 receptor agonists (GLP-1s) like semaglutide help people lose weight more effectively than earlier medications, that rapid weight loss has been linked to thinner bones and increased fracture risk. But semaglutide appears to buck that trend, suggesting the drug may offer weight loss benefits without the bone penalty—a development that could reshape how doctors approach obesity and diabetes treatment.
Dr. Jairo Noreña and his colleagues at Stanford analyzed data from over 161 million patients tracked across U.S. community hospitals and academic medical centers between January 2016 and December 2023. They compared adults with type 2 diabetes taking semaglutide (26,324 patients) against those using other medications: dulaglutide, phentermine/topiramate, or bupropion/naltrexone (33,555 patients). None had prior fracture histories or osteoporosis diagnoses. The results were striking: semaglutide patients experienced 794 fractures, while the control group recorded 1,045—a clear protective effect despite the greater weight loss achieved by semaglutide users.
"Bone fractures are painful, expensive and can seriously affect quality of life—especially as people get older," Noreña said, capturing why this matters for millions struggling with both diabetes and obesity. The financial and personal toll of fractures extends far beyond the break itself: recovery time, mobility loss, infection risk, and long-term disability disproportionately affect older adults—the very population most likely to have type 2 diabetes.
The mechanism remains an open question. Semaglutide clearly produced greater reductions in body mass index than its competitors, yet somehow protected bone density rather than eroding it. Researchers suspect the rate and character of semaglutide-induced weight loss may differ from that of older medications, preserving bone mass even as the scale drops. But they're calling for confirmation through prospective studies designed specifically to track bone health alongside weight changes.
The findings arrive at a pivotal moment for obesity medicine. GLP-1s have become blockbuster treatments, with millions taking semaglutide (marketed as Ozempic and Wegovy) or similar drugs. Yet bone health has remained a nagging concern for prescribers—one that could deter patients or limit treatment duration. If semaglutide's bone-protective effect holds up under closer scrutiny, it could become a significant advantage, offering sustained weight loss without sacrificing skeletal integrity.
"This work is an important early step toward understanding the impact of semaglutide-induced weight loss on bone health in patients with type 2 diabetes," Noreña said, framing the study as a beginning rather than a conclusion. That measured tone reflects good science: promising data that points toward a better future while acknowledging the need for deeper investigation. For people juggling diabetes, excess weight, and the fear of fractures, that future looks a little brighter today.